A detailed history of Susquehanna Fundamental Investments, LLC transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Susquehanna Fundamental Investments, LLC holds 225,367 shares of STRO stock, worth $423,689. This represents 0.02% of its overall portfolio holdings.

Number of Shares
225,367
Previous 126,459 78.21%
Holding current value
$423,689
Previous $714 Million 7.58%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$2.92 - $5.33 $288,811 - $527,179
98,908 Added 78.21%
225,367 $660 Million
Q1 2024

May 07, 2024

BUY
$3.27 - $5.65 $413,520 - $714,493
126,459 New
126,459 $714 Million
Q3 2023

Nov 14, 2023

SELL
$3.29 - $4.9 $6,158 - $9,172
-1,872 Reduced 2.56%
71,113 $246,000
Q1 2023

May 16, 2023

SELL
$4.48 - $8.45 $18,273 - $34,467
-4,079 Reduced 5.29%
72,985 $337,000
Q4 2022

Feb 14, 2023

BUY
$5.41 - $8.08 $416,916 - $622,677
77,064 New
77,064 $622,000
Q1 2022

May 16, 2022

SELL
$7.78 - $15.31 $139,946 - $275,396
-17,988 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$14.25 - $23.53 $274,269 - $452,881
-19,247 Reduced 51.69%
17,988 $268,000
Q3 2021

Nov 15, 2021

SELL
$16.88 - $22.38 $184,852 - $245,083
-10,951 Reduced 22.73%
37,235 $703,000
Q2 2021

Aug 11, 2021

SELL
$18.03 - $23.82 $49,816 - $65,814
-2,763 Reduced 5.42%
48,186 $896,000
Q1 2021

May 17, 2021

SELL
$20.29 - $27.54 $257,622 - $349,675
-12,697 Reduced 19.95%
50,949 $1.16 Million
Q4 2020

Feb 16, 2021

BUY
$10.16 - $23.98 $218,602 - $515,953
21,516 Added 51.07%
63,646 $1.38 Million
Q3 2020

Nov 16, 2020

BUY
$7.44 - $13.15 $313,447 - $554,009
42,130 New
42,130 $423,000

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $98.1M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.